Although strategies targeting CB1R/PPARα have been explored in further depth for the treatment of obesity, the concomitant modulation of CB1R and PPARγ may also be useful for the control of metabolic syndrome and related disorders. Here, PPARA is linked to obesity due to melanocortin 4 receptor deficiency.